M

MacroGenics
D

MGNX

3.23000
USD
0.03
(0.78%)
Market Closed
Volume
13,108
EPS
-1
Div Yield
-
P/E
-2
Market Cap
202,725,937
OverviewSignalsIdeasNews
Related Instruments
    A
    ARRY
    -0.79000
    (-10.35%)
    6.84500 USD
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    I
    IMGN
    0
    (0%)
    0.000000 USD
    N
    NKTR
    -0.11000
    (-9.36%)
    1.06500 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    X
    XNCR
    -0.420
    (-1.79%)
    23.090 USD
    More
News

Title: MacroGenics

Sector: Healthcare
Industry: Biotechnology
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).